Therapeuticsmd Inc (TXMD) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access TXMD Annual Balance Sheets →
This page allows investors to track Therapeuticsmd Inc's balance sheet development across multiple reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent9.19
Cash & Short-term Investments9.00
Other Current Assets2.87
Prepaid Expense And Other Assets Current4.06
Total Current Assets16.12
Intangible Assets3.56
Other Assets, Noncurrent17.85
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Royalty Receivable Current Portion3.21
Operating Lease Right Of Use Asset5.06
Total Assets37.53
Liabilities
Accounts Payable, Current AC0.46
Accrued Liabilities And Other Liabilities0.43
Other Liabilities, Current1.45
Disposal Group, Including Discontinued Operation, Liabilities, Current LI2.67
Total Current Liabilities5.00
Total Long-term Debt0.00
Other liabilities, Noncurrent5.39
Operating Lease Liability Noncurrent4.82
Total Liabilities10.40
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock979.26
Retained Earnings / Accumulated Deficit-952.14
Other Equity0.00
Common Stockholder's Equity27.13
Total Stockholder's Equity27.13
Liabilities & Stockholder's Equity37.53
4 historic quarters locked

Sign in to unlock the full Therapeuticsmd Inc balance sheet history.

About Therapeuticsmd Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001213900-26-087768

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.